Topic: Anthem Blue Cross

4 chapters across the catalog

Friendshoring
Episode 1664 37:25 - 40:16

1664: Friendshoring

Anthem Blue Cross, Vaccine Provider Incentives and Doctor Bonuses

Documents from Anthem Blue Cross and Blue Shield outline a "COVID-19 Vaccine Provider Incentive Program" that paid doctors cash bonuses based on the percentage of their patients vaccinated. The progressive payment structure offered up to $250 per newly vaccinated member if a practice reached a 75% vaccination threshold. Critics argue these financial rewards compromised medical ethics by incentivizing doctors to push treatments for profit.

Kunzite
Episode 693 1:48:05 - 1:51:55

693: Kunzite

Anthem Blue Cross Hack, Medical Record Security, Theodore Kaczynski

The massive data breach at Anthem Blue Cross, affecting 80 million customers, is discussed as a failure of electronic medical record mandates. The hosts reference Theodore Kaczynski’s "Industrial Society and Its Future," arguing that the more society relies on technology and the cloud, the more vulnerable private information becomes.

HAARP-ing on Earthquakes
Episode 178 1:46:03 - 1:50:46

178: HAARP-ing on Earthquakes

Anthem Blue Cross Rate Hikes, Pharmaceutical Pricing Scams

A deconstruction of the 39% rate increase by Anthem Blue Cross focuses on the relationship between insurance companies and pharmaceutical pricing. Dvorak shares a personal anecdote about the cost of a generic Retin-A cream jumping from $15 to $125. He argues that insurance companies encourage high drug prices to increase their total revenue while maintaining a fixed 2-5% profit margin.

Ron Paul For President
Episode 176 1:36:12 - 1:41:12

176: Ron Paul For President

Anthem Blue Cross Rate Hikes and Health Care Reform

President Obama's weekly address focused on Anthem Blue Cross raising premiums by up to 39% in California. The hosts theorize that these "outrageous" rate hikes are a coordinated effort to revive the "public option" in health care reform. They suggest the insurance industry may be in on the scheme to secure government-managed profits, potentially involving Goldman Sachs.